Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/DRKS00000162
DRKS00000162CompletedPhase 2

Phase-IIb-Study to Evaluate the Effect of a Neoadjuvant Chemotherapy with Docetaxel, Epirubicine and Cyclphosphamide (TEC) in Patients with primary HER-2 neu Negative Mammacarcinoma - NeoTEC

niversität Leipzig0 sites152 target enrollmentStarted: July 20, 2009Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 2
Status
Completed
Sponsor
Enrollment
152
Study OverviewStudy DesignEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
N/a: Single Arm Study
Masking
Open (masking not used)

Eligibility Criteria

Ages
18 Years to one (—)
Sex
Female

Inclusion Criteria

  • •Women with histologically verified mamma carcinoma (assessment of estrogen and progesterone receptors, grading, negative HER-2/neu status)
  • •- All receptor-negative mamma carcinoma starting from cT1c, all receptor-positive mamma carcinoma starting from cT3, cT4 includes inflammatory mamma carcinoma
  • •- In case of cT2 and receptor-positivity, N+ is required and can also be detected with sentinel node biopsy
  • •- In case of cT1c and receptor-positivity, a positive lymph node must be verified with sentinel node biopsy (pNsn+)
  • •- Clinically and with an imaging technology (sonography or mammography) measurable primary tumor
  • •- Sufficient bone marrow reserve: number of neutrophils higher/equal 1,5 x 1000000000/L, number of thrombocytes higher/equal 100 x 1000000000/L, hemoglobin higher/equal 6,2 mmol/L
  • •- Sufficient liver and renal function: bilirubin smaller/equal 1 x upper limit of quantification (ULQ), ASAT (SGOT) and ALAT (SGPT) smaller 1,5 x ULQ, alcalic phosphatase smaller 1,5 x ULQ, Creatinine smaller 1 x ULQ (if creatinine higher ULQ creatinine clearance must be higher 60 mL/minute)
  • •- Age-appropriate cardiologically normal findings as documented by ECG and LVEF (echocardiographical) assessments before beginning the therapy
  • •- ECOG-performance-status of 0-2
  • •- Age greater/equal 18 years
  • •- Written informed consent of the patient including compliance of the patient regarding the therapy and the follow-up must be available before enrolment and documented according to the local regulations.

Exclusion Criteria

  • •Pregnant or nursing women. Positive pregnancy test (urine or serum) within 7 days before registration
  • •- Previous surgical, cytostatic or hormonal therapy (with exception of hormone substitution or contraception), no previous immune or radiation therapy
  • •- Women with child bearing potency (menopause according to hormone status) without effective non-hormonal contraception (intra-uterine devices such as spirals, condoms in combination with additional contraceptic measures, vasectomised partner) during the participation in the study and 6 months after the end of study therapy.
  • •- Bilateral localisation of tumors
  • •- Evidence of distant metastases after complete staging with chest X-ray, upper abdomen sonography, and/or CT and bone scintigraphy
  • •- Pre-existing motor or sensor neurotoxicity > grade 2 (according to NCl criteria)
  • •- Pre-existing cardiac disease not permitting the participation in this study (e.g. severe heart insufficiency or unstable angina pectoris, cardiac infarction within one year before study entry, uncontrolled hypertension, therapy resistant arrhythmia
  • •- Significant neurological or psychiatric disease in the anamnesis (including psychotic disorders, dementia or seizures) compromising the understanding of the trial and consent to the trial.
  • •- Drug abuse
  • •- Active infection
  • •- Florid ulcus, unstable diabetes mellitus
  • •- Previously diagnosed tumor with exception of basalioma or in situ carcinoma of the cervix or other cancers having been treated curatively and having been followed by a disease-free interval of < 10 years.
  • •- Chronic treatment with corticosteroids if not started > 6 months before study entry and at low doses (< 20 mg Methylprednisolone or equivalents)
  • •- Clear contraindication for the application of corticosteroids
  • •- Contraindication of the planned therapy:
  • •- hypersensitivity to one of the trial drugs (Docetaxel, Cyclophosphamide and Epirubicine)
  • •- extensive inflammatory condition of oral or gastrointestinal mucous membrane
  • •- Lack of compliance
  • •- Concomitant participation in other clinical trials

Investigators

Sponsor
niversität Leipzig

Similar Trials

Active, not recruiting
Phase 1
Phase-IIb-Study to Evaluate the Effect of a Neoadjuvant Chemotherapy with Docetaxel, Epirubicine and Cyclphosphamide (TEC) in Patients with primary HER-2 neu Negative MammacarcinomaPhase-IIb-Studie zur Erfassung der Effektivität einer neoadjuvanten Chemotherapie mit Docetaxel, Epirubicin und Cyclophosphamid (TEC) bei Patientinnen mit primärem HER- 2 neu negativem MammakarzinomPrimary mamma carcinomaMedDRA version: 14.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2008-003064-19-DEniversität Leipzig
Recruiting
Phase 2
A study of neoadjuvant PEMbrolizumab before radical PROstatectomy (PEM-PRO) in patients affected by high-risk prostate cancer
2024-514580-26-00Ospedale San Raffaele S.r.l.59
Active, not recruiting
Phase 1
A phase II, single arm study investigating neoadjuvant plus adjuvant treatment with Cemiplimab in high risk, surgically resectable, stage III Cutaneaous Squamous Cell Carcinomahigh risk, surgically resectable, stage III Cutaneous Squamous Cell CarcinomaMedDRA version: 21.1Level: PTClassification code 10041834Term: Squamous cell carcinoma of skinSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2019-001469-34-ITFONDAZIONE MELANOMA ONLUS25
Active, not recruiting
Not Applicable
Phase IIa study to investigate the efficacy of NOX-H94 in the treatment of anemia in patients with cancer.anemia of chronic disease in patients with cancerMedDRA version: 16.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 100000004864MedDRA version: 16.0Level: LLTClassification code 10054310Term: Anemia of chronic diseaseSystem Organ Class: 100000004851
EUCTR2012-001525-27-ATOXXON Pharma AG48
Active, not recruiting
Phase 1
Phase IIa study to investigate the efficacy of NOX-H94 in the treatment of anemia in patients with cancer.
EUCTR2012-001525-27-BGOXXON Pharma AG48
Phase-IIb-Study to Evaluate the Effect of... | Clinical Trial